The cancer patient’s own drug sensitivity model
The cancer patient’s own drug sensitivity model: researchers from the Lothe lab and collaborators recently published a paper in Clinical Cancer Research describing ex vivo patient-derived organoids from colorectal liver metastases in a heterogeneity context. Drs. Jarle Bruun, Kushtrim Kryeziu and Peter W. Eide (photo) were shared 1st authors, and have established the PDO lineages and drug screen analyses.
Jørgen Smeby the first to defend his PhD digitally at the Institute for Cancer Research
The first digital PhD defence at the Institute for Cancer Research was held on the 20th of April 2020. Dr. Jørgen Smeby defended his thesis "Molecular subtype-dependent impact of driver mutations in colorectal cancer" submitted to the Faculty of Medicine, University of Oslo. The work was performed in the Lothe lab at the Institute for Cancer Research and the K. G. Jebsen Colorectal Cancer Research Centre.